Add this Podcast feed to your media player

Faced with economic pressures and budget constraints, biopharmaceutical companies are increasingly looking at outsourcing as a cost-effective alternative. In this interview, Ajit Mahadevan, Leader of Biotech initiatives for the India Life Sciences Practices at Ernst & Young, discusses current trends and challenges of outsourcing biomanufacturing-related activities to India.

Click here to go to the main podcast page >>>